DOSAGE
Adults: The usual dosage is 300 mg/day
and can be increased exceptionally up to 600 mg/day.
Recommended duration of use is 3 days. In the absence
of any warning sign, the maximum duration of use will be 7
days.
ADMINISTRATION
TRIMEBOSTON 300 is administered orally.
CONTRADICATIONS
Hypersensitivity to the active substance or to any of the
excipients mentioned.
WARNINGS AND PRECAUTIONS
This medicine contains lactose. Its use is not
recommended in patients with galactose intolerance, Lapp
lactase deficiency or glucose or galactose malabsorption
syndrome (rare hereditary diseases).
INTERACTIONS
Not applicable.
PREGNANCY AND LACTATION
Pregnancy
Studies in animals have not shown any teratogenic effect.
There are currently no sufficiently relevant data to
evaluate a possible malformative or fetotoxic effect of
trimebutine when administered during pregnancy.
Therefore, as a precautionary measure, it is preferable
not to use trimebutine during the first trimester of
pregnancy. In the absence of adverse effects expected
for the mother or child, use of trimebutine during the
second and third trimesters of pregnancy should be
considered only when necessary.
Lactation
The passage into the breast milk of trimebutine is not
known.
As a precautionary measure, it is preferable to avoid
using trimebutine during breast-feeding.
UNDESIRABLE EFECTS
Frequency are defined as: very common (≥1 /
10), common (≥1 / 100 to <1/10), uncommon (≥1
/ 1000 to <1/100), rare (≥1 / 10000 to
<1/1000), very rare
(<1/10000); indeterminate frequency (can not be
estimated from the available data).
|
Body System
|
Undesirable Effect
|
Frequency
|
|
Immune system disorders
|
Hypersensitivity reactions (pruritus, urticaria,
angioedema and exceptionally anaphylactic shock).
|
Not known
|
|
Skin and subcutaneous tissue
disorders
|
Rash
|
Uncommon
|
|
Generalized maculopapular rash, erythema,
eczematiform reactions and exceptionally severe
skin reactions including cases of acute
generalized acute exanthematous pustulosis (PEAG),
erythema multiforme,febrile toxiderma.
|
Uncommon
|
OVERDOSE AND TREATMENT
Symptoms
In case of overdose, bradycardia-type cardiac disorders,
QTc prolongation, or tachycardia and neurological
disorders such as somnolence, convulsion and coma could be
observed.
Treatment
Surveillance in specialized settings is necessary and
symptomatic treatment should be implemented.
STORAGE CONDITION
In a dry place, below 30 °C, protect from light.
SHELF- LIFE
36 months from the manufacturing date. Do not use after
the expiry date.